A small controlled trial finds a ceramide signal in impaired skin barriers
In a 50-person split-body trial, both the test emollient and vehicle improved symptoms; the ceramide formula was associated with lower water loss in participants with impaired barriers.
In a 50-person split-body trial, both the test emollient and vehicle improved symptoms; the ceramide formula was associated with lower water loss in participants with impaired barriers.
Why it matters
The vehicle response keeps the interpretation honest: formulation base and regular emollient use may matter alongside a highlighted ingredient.
What we don't know
The study was small and single-center; three coauthors list Evonik Operations affiliations, and the exploratory microbiome findings do not yet have established clinical importance.
The design
Fifty participants used a Ceramide NP C15 emollient and a vehicle in a randomized, double-blind, split-body design for six weeks. The researchers measured symptoms and barrier physiology and explored bacterial community changes with two profiling methods.
The measured result
Both sides improved on subjective symptoms. Among participants with impaired barrier function, the ceramide formula was associated with a significant reduction in transepidermal water loss. Exploratory microbiome analyses found modest treatment-associated differences.
This is encouraging but not a category-wide verdict. The exact formula, population, comparator, and subgroup all shape the result.
Open the source file
These links support the claims above. Source dates, disclosures and limits are documented in the article and source list.